Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Ruff Analyzes Overall Survival in the VELOUR Trial

February 1st 2013

Paul Ruff, MD, from the Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival following treatment with ziv-aflibercept in patients with metastatic colorectal cancer, as observed in the VELOUR trial.

Dr. Kim on the Investigation of Regorafenib in mCRC

January 31st 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

Extended Survival Benefit With Zaltrap Seen in Metastatic Colorectal Cancer

January 28th 2013

Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.

Dr. Grothey on the Time Course of Regorafenib-Associated AEs

January 28th 2013

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses the time course of adverse events following treatment with regorafenib, as observed in the CORRECT study.

Dr. Grady Discusses Molecular Subtypes in Colorectal Cancer

January 25th 2013

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.

Colorectal Cancer Prognosis and Response to Chemotherapy Vary by Molecular Subtype

January 24th 2013

Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.

Study Finds Role for Maintenance Bevacizumab in mCRC

January 16th 2013

A combination of maintenance bevacizumab plus standard second-line chemotherapy appears to be an effective strategy in managing patients with metastatic colorectal cancer after disease progression

Dr. Holcombe Discusses Aflibercept for mCRC

January 14th 2013

Randall F. Holcombe, MD, Tisch Cancer Institute at Mount Sinai Medical Center, speaks about the use of aflibercept in patients with metastatic colorectal cancer.

Controlling Progression in Patients With Metastatic Colorectal Cancer

December 21st 2012

The prognosis for patients with colorectal cancer has benefited greatly from the advent of advances in chemotherapy and new agents, with nearly threefourths of stage I patients surviving for at least 5 years after diagnosis.

Biomarker May Predict Response to Bevacizumab in mCRC

November 26th 2012

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer (mCRC) treated with bevacizumab (Avastin), suggesting that patients who have the appropriate biomarker could experience a greater benefit when given the drug, whereas others who do not express the biomarker could be spared from receiving unnecessary therapy.

Dr. Holcombe on Regorafenib for Colorectal Cancer

November 9th 2012

Randall F. Holcombe, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the oral multikinase inhibitor regorafenib for patients with metastatic colorectal cancer.

Potential Biomarker for Response to Bevacizumab in Colorectal Cancer Identified

October 25th 2012

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Laxative-Free CTC Examined as Potential Alternative to Standard Colonoscopy

October 25th 2012

Computer-aided computed tomographic colonography that does not require a laxative preparation nearly rivals conventional optical colonoscopy for identifying asymptomatic adults with adenomas.

Dr. Nancy Lewis Discusses the Regorafenib CORRECT Trial

October 18th 2012

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.

Adjuvant Chemotherapy May Offer Survival Benefit in Older Patients With Colon Cancer

October 17th 2012

Patients 75 years of age or older with stage III colon cancer may expect a survival benefit from adjuvant chemotherapy that rivals that previously reported in younger patients.

Updated Regorafenib Survival Results Confirm Effectiveness

October 1st 2012

Patients with heavily pretreated metastatic colorectal cancer who received regorafenib experienced a sustained survival benefit across all prespecified subgroups.

FDA Approves Regorafenib for Advanced Colorectal Cancer

September 27th 2012

The FDA has approved regorafenib, an oral multikinase inhibitor, to treat patients with metastatic colorectal cancer whose disease has progressed after prior therapy.

Colonoscopy Linked With Lower Risk of Colorectal Cancer Mortality

August 24th 2012

Colonoscopy is effective for the prevention of colorectal cancer deaths, according to the results of a large, population-based, case-control study.

Regorafenib Extends Survival in Colorectal Cancer, Delays Disease Progression in GIST

August 7th 2012

The oral multikinase inhibitor regorafenib extended OS in patients with metastatic colorectal cancer and improved PFS in patients with gastrointestinal stromal tumors.

FDA Approves Aflibercept for Metastastic Colorectal Cancer

August 3rd 2012

The FDA announced that aflibercept has been approved to treat metastatic colorectal cancer when given in combination with the FOLFIRI chemotherapy regimen.